

WELCOME TO OSLO BIO

YOUR KEY TO THE

LIFE SCIENCE

COMMUNITY IN OSLO



OSLO
BIO

OSLO BIO BOARD MEMBERS

Head of Oslo Bio
Professor Anne-Brit Kolstø
University of Oslo
a.b.kolsto@farmasi.uio.no

Stein Vaaler
MedCoast Scandinavia
stein.vaaler@ahus.no

Bjarte Reve
Oslo Cancer Cluster
bjarte.reve@radforsk.no

Kjetil Taskén
The Biotechnology Center of
Oslo (BiO)
kjetil.tasken@biotek.uio.no

Øystein Lie
MareLife
ol@oslo.teknopol.no

Henrik Lund
Former Global VP in
Clinical development
at AstraZeneca.
CEO, Bionor Pharma ASA,
Chairman of the Board,
DiaGenic ASA,
henriklu@online.no

Wilhelm Wold
Innovation Norway
wilhelm.r.wold@
innovasjon norge.no

COOPERATION PARTNERS

Norwegian Bioindustry Association

The Research Council of Norway

Innovation Norway

MedCoast Scandinavia

CONTACT

Morten Fraas
mf@oslo.teknopol.no
Tel: +47 22 00 29 97

Susanne Werner
sw@oslo.teknopol.no
Tel: +47 22 00 29 86





Oslo Bio is a collaborative network of stakeholders from the life science cluster in the region of Oslo, Norway's capital. The members are **Oslo Cancer Cluster**, **Nansen Neuroscience Network**, **Oslo Medtech** and **MareLife**.

The network aims to strengthen the cluster and contribute to long term growth through marketing, initiating and facilitating development projects and international collaboration. Oslo Teknopol acts as the secretariat for Oslo Bio.

ABOUT LIFE SCIENCE IN THE OSLO REGION

“In Oslo you have access to top international competence in critical disciplines. This means access to both permanent employees and the necessary consultants. Proximity to investors and the Oslo Stock Exchange means easier access to capital, and makes follow-up of investors easier.”

Bernt-Olav Røttingsnes, CFO, PCI Biotech Holding ASA

“Oslo and Norway show the fastest implementation of new pharmaceutical therapies of any country in Scandinavia, and Oslo is an ideal location to execute clinical trials”.

Henrik Lund, former Global Vice President, Clinical Development, AstraZeneca (VP Clinical MC, AstraZeneca R&D)



“We have been able to build something exciting from scratch - this is what everybody dreams of. The standard of Norwegian biomedical research has skyrocketed in the last years. Oslo is a good place for biotech. A lot is going to happen in the coming years.”

Stefan Krauss, Managing Director,
Cancer Stem Cell Innovation Center





OSLO CANCER CLUSTER (OCC) FROM CANCER RESEARCH TO CURE


Oslo Cancer Cluster is a non-profit member organization dedicated to accelerate the development of new cancer diagnostics and medicines. We will achieve this through:

- Local collaboration and international partnership.
- Increasing our member companies' ability to attract capital.
- Creating an efficient clinical trials network to shorten development timelines.
- Building Oslo Cancer Cluster Innovation Park bridging research, biopharma and education.

Oslo Cancer Cluster, a Norwegian Centre of Expertise (NCE) has over 60 members in Norway and abroad, including academic research institutions, industrial companies, health initiatives and support groups, all with the main focus on cancer.

Over 70% of all cancer research in Norway is done in the Oslo-region, and the members of Oslo Cancer Cluster have a large R&D pipeline with around 50 projects in preclinical and clinical phases.

www.oslocancercluster.no



OSLO MEDTECH

FOR BETTER LIVING AND BETTER HEALTHCARE

Oslo Medtech is a cluster that consists of companies, hospitals, investment firms, as well as knowledge and research institutions – all with a focus on medical technology and innovation.

Norway, together with the rest of the world, faces major health challenges related to handling of an aging population, large population diseases and dramatic cost increases in health care. The Oslo medtech cluster addresses these issues, facilitating cooperation within the areas of R & D, industry expertise, and technology: to be used in new products, services and systems that can contribute to solving challenges within health care.

Oslo Medtech works to facilitates close cooperation between the cluster participants, generating cooperation between medical-technical industry and health care, initiating innovative processes, and contributing to the development of products and services in medical technology. The cluster's goal is that these activities will contribute to a more efficient Norwegian health care system and be able to deal with future major health challenges, while continually developing that Norwegian medical-technical industry.

Oslo Medtech's ambition is to contribute to the development of major, internationally recognized and competitive medical-technical industry in Norway.

www.oslomedtech.no



MARELIFE

BIO MARINE INNOVATIVE NETWORK

MareLife is a uniquely composed and independent marine innovation network organized as a member organization which embraces all marine sectors: fishery, aquaculture and marine ingredients, all with their entire value chain. The member structure is composed of trend-setting producers and solution providers, capital owners and academia in collaboration with the public sector.

MareLife works in four major ways: facilitating collaboration between members with emphasis on research projects, assisting in start up processes, collaborating with authorities to optimize frameworks for innovation, and communicating its efforts.

www.marelife.no

NANSEN NEUROSCIENCE NETWORK ...WORKING HARD FOR A HEALTHY BRAIN

Nansen Neuroscience Network is founded as an independent organization by industry, academic research groups and clinicians with a particular and expertise interest in neuroscience.

This network is organized as a knowledge network aiming to connect brain science and industry. Nansen Neuroscience Network is committed to improve quality of life through innovation, research and development of diagnostics, therapeutics, and preventive measures.

The Nansen Neuroscience Network, was established in May 2010, and as of August 2010 the network has more than 30 members (organizations).

The Norwegian community can claim particular strengths in brain physiology, in vivo neuro imaging, memory and cognitive functions, biomarkers, DNA repairs and preventive medicine. Among the members there is a wide range of different organizations working in neuroscience including smart ups, small companies on the local stock exchange, international pharmaceutical and medtech companies and leading academic institution with pre-clinical and clinical focus.

www.nansenneuro.net



OSLO - BUILDING ON UNIQUE STRENGTHS

Norway and its largest life sciences market, the Oslo region, are characterised by their outstanding level of biomedical research and valuable discoveries within the life sciences.

REGIONAL FACTS

The members of Oslo Cancer Cluster have a large R&D pipeline with around 50 projects in preclinical and clinical phases.

Four of the key discoveries worldwide in Neuroscience were made by Oslo-based scientists.

Based on pivotal expertise from the Oslo region, Norway is one of the world leaders within bio marine activities and home to two of few fishbreedings companies worldwide.

Europe's most modern hospital Akershus, fully digitalized and highly attractive as testbed for medtech companies.

Oslo University Hospital group is Europe's largest with 19.000 employees, with 1500 working within research , 1400 research articles produced annually, and 100 PhD's awarded each year on a total budget of 1900 million Euros.

70% of people employed in Norwegian biotech sector are based in the Oslo region.

16 of Norway's 200 biotech and medtech companies are listed.

Tax deduction, R&D expenses in all enterprises, which are eligible for Norwegian taxation.

One of Europe's most highly educated workforces.



Nansen
Neuroscience
Network

...working hard for a Healthy Brain



Oslo**medtech**



Oslo Cancer Cluster

OSLO BIO
c/o Oslo Teknopol IKS,
P.O. Box 527 Sentrum,
N-0105 Oslo, Norway
Phone: +47 22 00 29 90
www.oslobio.no